Cliff Asness's KMTS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 32,447 shares of Kestra Medical Technologies, Ltd. (KMTS) worth $825,452, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Cliff Asness has maintained this position in KMTS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 32,447 shares. Largest reduction occurred in Q1 2026, reducing 8,340 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Kestra Medical Technologies (KMTS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kestra Medical Technologies (KMTS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +32,447 | New Buy | 32,447 | $25.44 |
| Q1 2026 | -8,340 | Sold Out | 0 | $0.00 |
| Q4 2025 | +8,340 | New Buy | 8,340 | $26.52 |
Cliff Asness's Kestra Medical Technologies Investment FAQs
Cliff Asness first purchased Kestra Medical Technologies, Ltd. (KMTS) in Q4 2025, acquiring 8,340 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Kestra Medical Technologies, Ltd. (KMTS) for 3 quarters since Q4 2025.
Cliff Asness's largest addition to Kestra Medical Technologies, Ltd. (KMTS) was in Q2 2026, adding 32,447 shares worth $825,452.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 32,447 shares of Kestra Medical Technologies, Ltd. (KMTS), valued at approximately $825,452.
As of the Q2 2026 filing, Kestra Medical Technologies, Ltd. (KMTS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Kestra Medical Technologies, Ltd. (KMTS) was 32,447 shares, as reported at the end of Q2 2026.